Navigation Links
Sequella receives US and EU orphan drug status for SQ109 for the treatment of TB
Date:10/22/2007

ROCKVILLE, MD -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat diseases of epidemic potential, announced today that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) independently reviewed Sequella lead drug compound, SQ109, and both agencies granted SQ109 orphan drug status for the treatment of tuberculosis. SQ109 shows excellent in vitro and in vivo activity against drug-susceptible and drug-resistant TB bacteria, including XDR-TB. Further, SQ109 synergizes with other TB drugs in experimental animal models of TB, and could result in new TB drug combinations that have much greater activity than the current standard of care.

We are pleased that the FDA and the EMEA awarded Sequella orphan drug and orphan medicinal product status for the use of SQ109 (N-adamantany1-N-Geranyl-ehtylendiamine) for the treatment of tuberculosis (TB), a chronically debilitating and life-threatening infectious pulmonary and extrapulmonary disease, said Dr. Carol Nacy. With the resurgence of TB in a new drug-resistant form it is clear there is a need to readdress the treatment of this infectious and deadly disease. To accelerate our clinical programs, we will continue to work closely with the FDAs Office of Orphan Products Development and the EMEAs Committee for Orphan Medicinal Products as we move through the clinical and regulatory process.

The Orphan Drug Act (Public Law 97-414, enacted in 1983 and amended) provides for economic incentives to encourage pharmaceutical companies to develop drugs for rare diseases defined as those affecting fewer than 200,000 people in the United States. Orphan drug designation entitles Sequella, Inc. to seven years of market exclusivity for SQ109 for the treatment of patients with tuberculosis. Additional incentives for orphan drug development include tax credits related to certain development expenses, an exemption from the FDA user fee, and
'/>"/>

Contact: Alicia Moran
alicia@brightlinemedia.com
410-991-7027
Sequella
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. DuPonts first biologically derived polymer receives global recognition
2. OneWorld Health drug receives Orphan designation from U.S. and European regulatory agencies
3. Research on antibiotics receives historical recognition
4. Anthrax test, developed by army and CDC, receives FDA approval
5. Research team receives $7.5 million to study cassava
6. Virulizin granted orphan drug status in Europe
7. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
8. Sudden change in social status triggers genetic response in male fish, study finds
9. Gene expression test reveals ER and HER-2 status of breast tumors
10. MU researchers to study the status of black bears in Missouri
11. Protein discovery could unlock the secret to better TB treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... most ideal source of nutrition for infants and ... the evolution and civilizations of human beings. Unlike ... number of bacterial species, including some opportunistic pathogens ... to scientists and physicians. , Indeed, the existence ... result of co-evolutionary and co-adaptive interactions between the ...
(Date:9/2/2014)... integrity? Tell the truth; everyone has a tipping point. We ... lie if the benefit is great enough. Now, scientists have ... that decision. , The result was published online this ... prefer to be honest, even if lying is beneficial," said ... at the Virginia Tech Carilion Research Institute , where ...
(Date:9/2/2014)... propensity for eating anything, including each other, camel crickets ... North Carolina State University finds that non-native camel cricket ... States. , "The good news is that camel crickets ... humans," says Dr. Mary Jane Epps, a postdoctoral researcher ... about the research. , The research stems from a ...
Breaking Biology News(10 mins):Are human breast milk microbiome 'neutral'? 2Are human breast milk microbiome 'neutral'? 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Researchers find Asian camel crickets now common in US homes 2
... the triangle depicting how many servings of each food ... knows about MyPlate - the circle showing what a healthy ... United States Department of Agriculture (USDA) to help American consumers ... icon that prompts us to think about what,s on our ...
... gene therapy holds promise for the treatment of devastating genetic ... have been unclear. In a study online December 26th ... by Cell Press, researchers evaluated a patient with a genetic ... after he had undergone a gene therapy procedure as part ...
... neurodegenerative disorders, and drugs without significant side effects ... Institute of Synergon Consulting in Romania, led by ... is a transcription co-activator required for consolidation of ... same time involved in DNA replication and repair, ...
Cached Biology News:Who is using MyPlate? 2Gene therapy for human skin disease produces long-term benefits 2
(Date:9/2/2014)... about a billionth of a meter in size, are ... can benefit human health, as in some innovative early ... through viruses, air pollution, traffic emissions, cosmetics, sunscreen and ... in St. Louis, led by Lan Yang, PhD, the ... Systems Engineering, and their collaborators at Tsinghua University in ...
(Date:9/2/2014)... Scientists, including University of Oregon chemist Geraldine Richmond, ... of self-assembling, synthetic proteins called peptoid nanosheets that ... accomplishment -- detailed this week in a paper ... Proceedings of the National Academy of Sciences ... of the two-dimensional peptoid nanosheets that can be ...
(Date:9/2/2014)... 2, 2014 Persistence Market Research ... in Pharmaceutical, Biopharma and Life Sciences: North ... the global membrane technology market for pharmaceutical, biopharma and life sciences ... is expected to grow at a CAGR of 9.1% ... of USD 10,886.0 million in 2019. Browse ...
(Date:9/2/2014)... AVENTURA, Fla. , Sept. 2, 2014  Technology ... has announced that its wholly-owned subsidiary Renuell Int,l, Inc. ... National Aeronautics and Space Administration ("NASA") at the Johnson ... See photos: tapplic.com/houstonphotos/ ... stated, "We are very pleased to announce our latest, ...
Breaking Biology Technology:Engineers develop new sensor to detect tiny individual nanoparticles 2Engineers develop new sensor to detect tiny individual nanoparticles 3UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3
... that it,has received the European CE Mark (Conformite Europeene) ... CE Mark certifies,that the product has met EU health, ... Granted in the Netherlands, the,registration will allow the system ... countries around the world that recognize the CE Mark. ...
... Calif., Oct. 29 Cliniqa Corporation (San,Marcos, ... is pleased to,announce the acquisition of the ... Diego, CA), a wholly owned subsidiary of ... manufacturer of clinical,diagnostic products focusing on clinical ...
... to Focus on Sales Growth and Product ... BioLife Solutions,Inc. (OTC Bulletin Board: BLFS), a ... and cryopreservation media products for,cells, tissues, and ... product,manufacturing, warehousing, and customer order fulfillment to ...
Cached Biology Technology:Diamics Receives European CE Mark Approval for Its Pap-Map(TM) System for Cervical Cancer Screening 2Cliniqa Corporation Completes Asset Acquisition of Reagents Applications, Inc. 2BioLife Solutions Outsourcing Manufacturing, Warehousing, and Order Fulfillment to Bioserv Corporation 2BioLife Solutions Outsourcing Manufacturing, Warehousing, and Order Fulfillment to Bioserv Corporation 3